Related Experiment Video

Updated: Jul 8, 2026

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats

A Bhatwadekar1, J V Glenn, J L Figarola

  • 1Centre for Vision Science, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road Belfast BT 126BA, Northern Ireland, UK. a.stitt@qub.ac.uk

The British Journal of Ophthalmology
|January 24, 2008
PubMed
Abstract

Insights

LR-90 effectively inhibits key lesions in experimental diabetic retinopathy by reducing acellular capillaries and restoring pericytes. This suggests LR-90 may prevent retinopathy in diabetic patients.

Area of Science:

  • Ophthalmology
  • Diabetology
  • Pharmacology

Background:

  • Diabetic retinopathy is linked to advanced glycation end product accumulation in retinal microvasculature.
  • LR-90 is a known inhibitor of advanced glycation with renoprotective and anti-inflammatory effects.

Purpose of the Study:

  • To investigate the impact of LR-90 on the progression of experimental diabetic retinopathy.
  • To evaluate LR-90's efficacy in mitigating diabetic retinopathy-associated vascular changes.

Main Methods:

  • Streptozotocin-induced diabetic rats received LR-90 in drinking water for 32 weeks.
  • Eyes were analyzed for acellular capillaries and pericyte counts via trypsin digestion and microscopy.

Main Results:

  • LR-90 treatment significantly reduced acellular capillaries in diabetic rats (1.63 vs. 2.58, p<0.05).
  • LR-90 treatment improved pericyte counts, restoring deficits observed in diabetic controls (24.19 vs. 18.12, p<0.001).

Conclusions:

  • LR-90 effectively inhibits critical pathological lesions in experimental diabetic retinopathy.
  • LR-90 demonstrates potential as a therapeutic agent for preventing diabetic retinopathy.

More Related Videos

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...